Bellerophon Therapeutics 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Craig Jalbert

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

CEO

Craig Jalbert (62 yo)

less than a year

테뉴어

Mr. Craig R. Jalbert is President, Treasurer, CS, Principal Executive Officer, Financial Officer, & Principal Accounting Officer of NexImmune, Inc. from August 27, 2024 He is Chief Executive Officer, Presi...

Bellerophon Therapeutics 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Bellerophon Therapeutics, Inc. Announces Executive Changes

Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board

Insufficient new directors

Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director

Insider recently sold US$82k worth of stock

Insufficient new directors

Recent updates

Bellerophon Therapeutics, Inc. Files Form 15

Bellerophon Therapeutics, Inc. Announces Executive Changes

Nasdaq Determines to Delist the Bellerophon Therapeutics from Nasdaq Capital Market

Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board

Insufficient new directors

New major risk - Financial position

New major risk - Revenue and earnings growth

Bellerophon Therapeutics to Be Delisted from the Nasdaq Capital Market At Opening of Business on July 28, 2023 Unless It Timely Requests A Hearing Before Nasdaq Hearings Panel to Address Deficiencies and Present Plan to Regain Compliance

Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director

New major risk - Financial position

Bellerophon Therapeutics, Inc. Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

Insider recently sold US$82k worth of stock

Bellerophon Therapeutics, Inc. Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Forecast to breakeven in 2025

Insufficient new directors

Bellerophon Therapeutics, Inc. Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse(R) in Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Insufficient new directors

Insufficient new directors

Bellerophon Provides Clinical Program Update

Insufficient new directors

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 Rebuild Study of Inopulse for Treatment of Fibrotic Interstitial Lung Disease

Insufficient new directors

Insufficient new directors

Bellerophon Therapeutics, Inc. Announces New Board Appointment

Insufficient new directors

Bellerophon Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Insufficient new directors

Bellerophon Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of Inopulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis

Bellerophon Therapeutics, Inc. Provides Clinical Program Update

Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) dropped from Russell 3000E Index

Chairman of the Board Jonathan Peacock has left the company

Bellerophon Therapeutics, Inc. Provides Clinical Program Update

Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics, Inc. Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse for the Treatment of COVID-19

CEO

테뉴어